January 24, 2017
Vectura starts with testing asthma drug/device combination for children
Vectura Group is moving on with researching and testing its VR647, a drug/device combination to treat asthma in children for the US market.
Pharmaceuticals, Biotechnology and Life Sciences
Vectura Group is moving on with researching and testing its VR647, a drug/device combination to treat asthma in children for the US market.
Galapagos has tested its filgotinib – JAK1 inhibitor – in a phase 2 study, for the patients with Chron’s disease, and…
Eli Lilly has presented detailed results of its disappointing phase 3 Expedition3 trial at the 9th Clinical Trials on Alzheimer’s…
Novartis on Wednesday announced positive results from the first large-scale study exploring the effects of directly switching symptomatic, non-frequently exacerbating…